Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00637377 |
This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.
Condition | Intervention | Phase |
---|---|---|
Macular Degeneration |
Drug: VEGF Trap-Eye Drug: Ranibizumab |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration (AMD). |
Estimated Enrollment: | 1200 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | July 2011 |
Estimated Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 3: Experimental |
Drug: VEGF Trap-Eye
2.0 mg VEGF Trap-Eye administered every 8 weeks (including one additional 2,0 mg dose at Week 4) during the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
Arm 1: Experimental |
Drug: VEGF Trap-Eye
0.5 mg VEGF Trap-Eye administered every 4 weeks during the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
Arm 2: Experimental |
Drug: VEGF Trap-Eye
2.0 mg VEGF Trap-Eye administered every 4 weeks during the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
Arm 4: Active Comparator |
Drug: Ranibizumab
0.5 mg administered every 4 weeks during the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
|
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Bayer Clinical Trial Contact | clinical-trials-contact@bayerhealthcare.com |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer Schering Pharma AG ( Therapeutic Area Head ) |
Study ID Numbers: | 91689, EurdaCT No.: 2007-000583-25 |
Study First Received: | March 12, 2008 |
Last Updated: | May 4, 2009 |
ClinicalTrials.gov Identifier: | NCT00637377 History of Changes |
Health Authority: | Switzerland: Ethikkommission |
Eye diseases Vision Impairment and Blindness Eyes and Vision |
Seniors Neovascular Age-Related Macular Degeneration (AMD) Retinal Disease |
Eye Diseases Mitogens Retinal Degeneration Macular Degeneration |
Blindness Endothelial Growth Factors Retinal Diseases Vision, Low |
Growth Substances Eye Diseases Physiological Effects of Drugs Retinal Degeneration |
Macular Degeneration Endothelial Growth Factors Pharmacologic Actions Retinal Diseases |